Workflow
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
SGMOSangamo Therapeutics(SGMO) ZACKS·2025-03-17 22:10

Group 1 - Sangamo Therapeutics reported a quarterly loss of 0.11pershare,whichwasworsethantheZacksConsensusEstimateofalossof0.11 per share, which was worse than the Zacks Consensus Estimate of a loss of 0.09, and an improvement from a loss of 0.34pershareayearago,indicatingasurpriseof−22.220.34 per share a year ago, indicating a surprise of -22.22% [1] - The company posted revenues of 7.55 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 52.51%, compared to revenues of 2.04millioninthesamequarterlastyear[2]−Overthelastfourquarters,SangamohassurpassedconsensusEPSestimatesonlyonceandhastoppedconsensusrevenueestimatesjustonce[2]Group2−Thestock′simmediatepricemovementwilldependonmanagement′scommentaryduringtheearningscall,withSangamoshareslosingabout3.82.04 million in the same quarter last year [2] - Over the last four quarters, Sangamo has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with Sangamo shares losing about 3.8% year-to-date, compared to a decline of -4.1% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -0.09 on 10millioninrevenues,andforthecurrentfiscalyear,itis−10 million in revenues, and for the current fiscal year, it is -0.26 on $56.63 million in revenues [7] - The Medical - Biomedical and Genetics industry, to which Sangamo belongs, is currently in the top 30% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]